Theriva Biologics (TOVX) Net Cash Flow (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Net Cash Flow of $1.4 million for Q1 2026, up 183.73% year-over-year from $496952.7 in Q1 2025, and down 74.71% quarter-over-quarter from $5.6 million in Q4 2025.
Theriva Biologics (TOVX) Net Cash Flow (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Net Cash Flow for 17 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 183.73% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $4.6 million (up 145.91% YoY), while the FY2025 annual figure was $1.5 million, up 113.01% from the prior year.
- Net Cash Flow slipped to $1.4 million in Q1 2026 per TOVX's latest filing, from $5.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $5.6 million in Q4 2025 and bottomed at -$10.6 million in Q1 2022.
- Historically, Net Cash Flow has averaged -$3.2 million across 5 years, with a median of -$3.5 million in 2024.
- On a YoY basis, Net Cash Flow climbed as much as 219.04% in 2025 and fell as far as 2177.16% in 2025.
- Theriva Biologics' Net Cash Flow stood at -$8.7 million in 2022, then gained by 7.92% to -$8.1 million in 2023, then soared by 41.84% to -$4.7 million in 2024, then jumped by 219.04% to $5.6 million in 2025, then tumbled by 74.71% to $1.4 million in 2026.
- Business Quant data shows TOVX's Net Cash Flow at $1.4 million in Q1 2026, $5.6 million in Q4 2025, and -$4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | -3.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.10 Mn |
| Jun 30, 2026 | -3.10 Mn |
| Mar 31, 2026 | 1.41 Mn |
| Mar 31, 2026 | 1.41 Mn |
| Dec 31, 2025 | 5.58 Mn |
| Dec 31, 2025 | 5.58 Mn |
| Sep 30, 2025 | -4.49 Mn |
| Sep 30, 2025 | -4.49 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Mar 31, 2025 | -1.68 Mn |
| Mar 31, 2025 | -1.68 Mn |
| Dec 31, 2024 | -4.68 Mn |
| Dec 31, 2024 | -4.68 Mn |
| Sep 30, 2024 | -197,000.00 |
| Sep 30, 2024 | -197,000.00 |
| Jun 30, 2024 | -3.45 Mn |
| Jun 30, 2024 | -3.45 Mn |
| Mar 31, 2024 | -4.88 Mn |
| Mar 31, 2024 | -4.88 Mn |